journal
https://read.qxmd.com/read/37731163/venetoclax-as-a-cytoreduction-therapy-for-acute-promyelocytic-leukaemia-a-single-centre-experience
#1
LETTER
Peijing Qi, Linya Wang, Hongqiao Li, Ying Wu, Jia Fan, Pengli Huang, Bei Hou, Mengjia Liu, Jie Yang, Huiqing Liu, Jiaole Yu, Wei Lin, Yuanyuan Zhang, Ruidong Zhang, Yu Lu, Qian Huang, Yan Liu, Huyong Zheng
No abstract text is available yet for this article.
September 20, 2023: British Journal of Haematology
https://read.qxmd.com/read/37731068/invasive-fungal-infection-following-venetoclax-and-posaconazole-co-administration
#2
JOURNAL ARTICLE
Gemma Reynolds, Karen F Urbancic, Chun Y Fong, Jason A Trubiano
The co-administration of venetoclax, a BCL-2 inhibitor, with a mould-active azole, such a posaconazole, has potential to both prevent invasive fungal infection (IFI) and reduce the required treatment dose, and cost, of venetoclax. Posaconazole drug-level monitoring is critical to ensuring adequate mould prophylaxis. A retrospective audit of 99 patients at a tertiary cancer centre, with myeloid malignancies co-prescribed venetoclax and posaconazole between January 2018 and April 2022, was undertaken to evaluate the adequacy of posaconazole prescribing and the rate of breakthrough IFI...
September 20, 2023: British Journal of Haematology
https://read.qxmd.com/read/37728227/potential-for-a-large-scale-newborn-screening-strategy-for-sickle-cell-disease-in-mali-a-comparative-diagnostic-performance-study-of-two-rapid-diagnostic-tests-sicklescan%C3%A2-and-hemotypesc%C3%A2-on-cord-blood
#3
JOURNAL ARTICLE
Aldiouma Guindo, Zenab Cisse, Ibrahima Keita, Sophie Desmonde, Yeya Dit Sadio Sarro, Boubacari A Touré, Mohamed Ag Baraika, Oumarou Tessougué, Pierre Guindo, Moussa Coulibaly, Oumar Traore, Niagalé Sylla, Mahamadou Diassana, Amaguiré Saye, Valentina Picot, Emilie Lauressergues, Valériane Leroy
Sickle cell disease (SCD) is a life-threatening disease requiring reliable early diagnosis. We assessed the acceptability and diagnostic performances of two rapid diagnostic tests (RDTs) to identify SCD (HbSS, HbSC, HbS/β-thalassaemia) or SCD carrier (HbS/HbC) in a pilot SCD newborn screening (NBS) strategy in Mali. All consenting delivering women were offered SCD NBS using cord blood sampling on two RDTs (SickleScan® and HemotypeSC®) compared to the high-performance liquid chromatography (HPLC) gold standard to detect SCD states...
September 20, 2023: British Journal of Haematology
https://read.qxmd.com/read/37726227/ratio-of-stemness-to-interferon-signalling-as-a-biomarker-and-therapeutic-target-of-myeloproliferative-neoplasm-progression-to-acute-myeloid-leukaemia
#4
JOURNAL ARTICLE
Fabíola Attié de Castro, Parinaz Mehdipour, Ankur Chakravarthy, Ilias Ettayebi, Helen Loo Yau, Tiago Silva Medina, Sajid A Marhon, Felipe Campos de Almeida, Thiago Mantello Bianco, Andrea G F Arruda, Rebecca Devlin, Lorena Lobo de Figueiredo-Pontes, Fernando Chahud, Maira da Costa Cacemiro, Mark D Minden, Vikas Gupta, Daniel D De Carvalho
Progression to aggressive secondary acute myeloid leukaemia (sAML) poses a significant challenge in the management of myeloproliferative neoplasms (MPNs). Since the physiopathology of MPN is closely linked to the activation of interferon (IFN) signalling and that AML initiation and aggressiveness is driven by leukaemia stem cells (LSCs), we investigated these pathways in MPN to sAML progression. We found that high IFN signalling correlated with low LSC signalling in MPN and AML samples, while MPN progression and AML transformation were characterized by decreased IFN signalling and increased LSC signature...
September 19, 2023: British Journal of Haematology
https://read.qxmd.com/read/37726004/clinical-and-clonal-characteristics-of-monoclonal-immunoglobulin-m-associated-type-i-cryoglobulinaemia
#5
JOURNAL ARTICLE
Jahanzaib Khwaja, Josephine M I Vos, Tessa E Pluimers, Nicole Japzon, Aisha Patel, Simon Salter, Arjan J Kwakernaak, Rajeev Gupta, Ali Rismani, Charalampia Kyriakou, Ashutosh D Wechalekar, Shirley D'Sa
Monoclonal immunoglobulin M-associated type I cryoglobulinaemia is poorly characterised. We screened 534 patients with monoclonal IgM disorders over a 9-year period and identified 134 patients with IgM type I cryoglobulins. Of these, 76% had Waldenström macroglobulinaemia (WM), 5% had other non-Hodgkin lymphoma (NHL) and 19% had IgM monoclonal gammopathy of undetermined significance (MGUS). Clinically relevant IgM-associated disorders (including cold agglutinin disease [CAD], anti-MAG antibodies, amyloidosis and Schnitzler syndrome) coexisted in 31%, more frequently in MGUS versus WM/NHL (72% vs...
September 19, 2023: British Journal of Haematology
https://read.qxmd.com/read/37723363/immune-thrombotic-thrombocytopenic-purpura-in-older-patients-results-from-the-spanish-ttp-registry-reptt
#6
JOURNAL ARTICLE
I Gómez-Seguí, E Francés Aracil, M E Mingot-Castellano, M Vara Pampliega, R Goterris Viciedo, F García Candel, C Pascual Izquierdo, J Del Río Garma, L Guerra Domínguez, I Vicuña Andrés, J Garcia-Arroba Peinado, S Zalba Marcos, J M Vidan Estévez, E González Arias, V Campuzano Saavedra, J M García Gala, S Ortega Sanchez, J Martínez Nieto, L Pardo Gambarte, M Solé Rodríguez, M Fernández-Docampo, L F Avila Idrovo, L Hernández, J Cid, J de la Rubia Comos
Immune thrombotic thrombocytopenic purpura (iTTP) is an ultra-rare disease that seldom occurs in the elderly. Few reports have studied the clinical course of iTTP in older patients. In this study, we have analysed the clinical characteristics at presentation and response to therapy in a series of 44 patients with iTTP ≥60 years at diagnosis from the Spanish TTP Registry and compared them with 209 patients with <60 years at diagnosis from the same Registry. Similar symptoms and laboratory results were described in both groups, except for a higher incidence of renal dysfunction among older patients (23% vs...
September 18, 2023: British Journal of Haematology
https://read.qxmd.com/read/37722599/oral-famotidine-reduces-the-plasma-level-of-soluble-p-selectin-in-children-with-sickle-cell-disease
#7
JOURNAL ARTICLE
Slimane Allali, Fabienne Marquant, Rachel Rignault-Bricard, Melissa Taylor, Joséphine Brice, Mariane de Montalembert, Thiago Trovati Maciel, Caroline Elie, Olivier Hermine
Plasma histamine levels are increased in patients with sickle cell disease (SCD), potentially promoting endothelial P-selectin expression and vaso-occlusion via histamine type 2 (H2) receptors. We conducted a prospective, non-comparative, single-centre study to determine whether famotidine, a H2 receptor antagonist, reduces P-selectin expression in SCD children. The median plasma P-selectin level was significantly reduced after 29 days of oral famotidine (53.2 ng/mL [IQR: 46.7-63.4] vs. 69.9 ng/mL [IQR: 53...
September 18, 2023: British Journal of Haematology
https://read.qxmd.com/read/37710381/venetoclax-plus-hypomethylating-agents-in-ddx41-mutated-acute-myeloid-leukaemia-and-myelodysplastic-syndrome-mayo-clinic-series-on-12-patients
#8
JOURNAL ARTICLE
Ahmad Nanaa, Rong He, James M Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J Hogan, Mark R Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B Alkhateeb
Venetoclax (VEN) is an FDA-approved selective inhibitor of B-cell leukaemia/lymphoma-2 (BCL-2), used for treating elderly or unfit acute myeloid leukaemia (AML) patients unable to undergo intensive chemotherapy. Combining VEN with hypomethylating agents (HMAs) has shown impressive response rates in high-risk myelodysplastic syndromes (MDS) and relapsed/refractory AML. However, the efficacy of VEN and HMAs in treating DDX41-mutated (mDDX41) MDS/AML patients remains uncertain. Despite the favourable prognostic nature of mDDX41 MDS/AML patients, there is a lack of clinical experience regarding their response to different treatment regimens, leading to an unknown optimal therapeutic approach...
September 14, 2023: British Journal of Haematology
https://read.qxmd.com/read/37700538/blinatumomab-differentially-modulates-peripheral-blood-and-bone-marrow-immune-cell-repertoire-a-campus-all-study
#9
JOURNAL ARTICLE
Darina Ocadlikova, Federico Lussana, Nicola Fracchiolla, Massimiliano Bonifacio, Lidia Santoro, Mario Delia, Sabina Chiaretti, Crescenza Pasciolla, Alessandro Cignetti, Fabio Forghieri, Francesco Grimaldi, Giulia Corradi, Letizia Zannoni, Stefania De Propris, Gian Maria Borleri, Ilaria Tanasi, Jayakumar Vadakekolathu, Sergio Rutella, Anna Rita Guarini, Robin Foà, Antonio Curti
Blinatumomab is the first bi-specific T-cell engager approved for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (B-ALL). Despite remarkable clinical results, the effects of blinatumomab on the host immune cell repertoire are not fully elucidated. In the present study, we characterized the peripheral blood (PB) and, for the first time, the bone marrow (BM) immune cell repertoire upon blinatumomab treatment. Twenty-nine patients with B-ALL received blinatumomab according to clinical practice...
September 12, 2023: British Journal of Haematology
https://read.qxmd.com/read/37699574/myeloperoxidase-creates-a-permissive-microenvironmental-niche-for-the-progression-of-multiple-myeloma
#10
JOURNAL ARTICLE
Connor M D Williams, Jacqueline E Noll, Alanah L Bradey, Jvaughn Duggan, Vicki J Wilczek, Makutiro G Masavuli, Branka Grubor-Bauk, Romana A Panagopoulos, Duncan R Hewett, Krzysztof M Mrozik, Andrew C W Zannettino, Kate Vandyke, Vasilios Panagopoulos
Expression of myeloperoxidase (MPO), a key inflammatory enzyme restricted to myeloid cells, is negatively associated with the development of solid tumours. Activated myeloid cell populations are increased in multiple myeloma (MM); however, the functional consequences of myeloid-derived MPO within the myeloma microenvironment are unknown. Here, the role of MPO in MM pathogenesis was investigated, and the capacity for pharmacological inhibition of MPO to impede MM progression was evaluated. In the 5TGM1-KaLwRij mouse model of myeloma, the early stages of tumour development were associated with an increase in CD11b+ myeloid cell populations and an increase in Mpo expression within the bone marrow (BM)...
September 12, 2023: British Journal of Haematology
https://read.qxmd.com/read/37697469/final-report-of-tki-discontinuation-trial-with-dasatinib-for-the-second-attempt-of-treatment-free-remission-after-failing-the-first-attempt-with-imatinib-treatment-free-remission-accomplished-by-dasatinib-trad-study
#11
JOURNAL ARTICLE
Maria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, Donna Forrest, Isabelle Bence-Bruckler, Lynn Savoie, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Pierre Laneuville, Kristjan Paulson, Tracy Stockley, Jeffrey H Lipton, Brian Leber, Dennis Dong Hwan Kim
Multiple studies have reported a significant treatment-free remission (TFR) rate of 50%-60% in patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitor (TKI) therapy. However, the remaining half of these patients still require re-initiation of TKI therapy for leukaemia control. It remains unclear if TKI drugs should be switched for re-therapy in patients who failed the first TFR (TFR1) attempt. Our study attempted to determine whether dasatinib therapy after TFR1 failure post-imatinib discontinuation could improve the likelihood of TFR2...
September 11, 2023: British Journal of Haematology
https://read.qxmd.com/read/37697431/lymphoplasmacytic-lymphoma-presenting-cold-agglutinin-syndrome-clonal-expansion-of-kmt2d-and-ighv4-34-mutations-after-covid-19
#12
LETTER
Kiyohito Hayashi, Daisuke Koyama, Yuki Sato, Masahiko Fukatsu, Takayuki Ikezoe
No abstract text is available yet for this article.
September 11, 2023: British Journal of Haematology
https://read.qxmd.com/read/37696766/disseminated-invasive-aspergillosis-in-a-patient-treated-with-ibrutinib-for-chronic-lymphocytic-leukaemia
#13
JOURNAL ARTICLE
Emily Booth, Matthijs Backx, Anurag Joshi, Hasan Nizami, Nagah Elmusharaf
No abstract text is available yet for this article.
September 11, 2023: British Journal of Haematology
https://read.qxmd.com/read/37696499/first-description-of-bone-marrow-failure-syndrome-in-spain-caused-by-mutations-in-the-ercc6l2-gene
#14
LETTER
Perla Bandini, Nina Borràs, Eugenia Fernandez Mellid, Laura Martin-Fernandez, Paula Melero Valentín, Natalia Comes, Lorena Ramírez, Patricia Cadahia Fernández, Matilde Rodríguez Ruiz, Manuel Mateo Perez Encinas, Francisco Vidal, Irene Corrales
No abstract text is available yet for this article.
September 11, 2023: British Journal of Haematology
https://read.qxmd.com/read/37694757/the-danish-national-haemoglobinopathy-screening-programme-report-from-16%C3%A2-years-of-screening-in-a-low-prevalence-non-endemic-region
#15
JOURNAL ARTICLE
Esther Agnethe Ejskjaer Gravholt, Jesper Petersen, Mathis Mottelson, Amina Nardo-Marino, Mathias Rathe, Marianne Olsen, Charlotte Holm, Finn Stener Jørgensen, Henrik Birgens, Andreas Glenthøj
The Danish national haemoglobinopathy screening programme seeks to determine parental haemoglobinopathy carrier state antenatally. In this retrospective register-based study, we evaluated the 16-year trajectory of this programme, utilising the Danish Red Blood Cell Centre's laboratory database, covering approximately 77% of the Danish population. During the study period, we observed a substantial increase in annual diagnostic examinations performed, from 389 in 2007 to 3030 in 2022. Women constituted 88% of these cases, aligning with the emphasis of the screening programme...
September 11, 2023: British Journal of Haematology
https://read.qxmd.com/read/37691342/cytidine-deaminase-status-as-a-marker-of-response-to-azacytidine-treatment-in-mds-and-aml-patients
#16
JOURNAL ARTICLE
Melanie Donnette, Mourad Hamimed, Joseph Ciccolini, Guillaume Sicard, Florian Correard, Laure Farnault, L'Houcine Ouafik, Geoffroy Venton, Raphaëlle Fanciullino
Azacitidine (Aza) is a mainstay of treatment for patients with acute myeloid leukaemia (AML) ineligible for induction chemotherapy and other high-risk myelodysplastic syndromes (MDS). Only half of patients respond, and almost all will eventually relapse. There are no predictive markers of response to Aza. Aza is detoxified in the liver by cytidine deaminase (CDA). Here, we investigated the association between CDA phenotype, toxicity and efficacy of Aza in real-world adult patients. Median overall survival (OS) was 15 months and 13 months in AML and high-risk MDS patients respectively...
September 10, 2023: British Journal of Haematology
https://read.qxmd.com/read/37691168/dramatic-response-to-intravenous-immunoglobulin-in-erythroblastic-synartesis
#17
LETTER
Clara Fontenaille, Benjamin De Sainte Marie, Marie Loosveld, Mikael Ebbo, Nicolas Schleinitz
No abstract text is available yet for this article.
September 10, 2023: British Journal of Haematology
https://read.qxmd.com/read/37691131/provider-prescription-of-hydroxyurea-in-youth-and-adults-with-sickle-cell-disease-a-review-of-prescription-barriers-and-facilitators
#18
REVIEW
Alex Pizzo, Jerlym S Porter, Yvonne Carroll, Adam Burcheri, Matthew P Smeltzer, Molly Beestrum, Chinonyelum Nwosu, Sherif M Badawy, Jane S Hankins, Lisa M Klesges, Nicole M Alberts
Sickle cell disease (SCD) is an inherited red blood cell disorder associated with frequent painful events and organ damage. Hydroxyurea (HU) is the recommended evidence-based treatment of SCD. However, among patients eligible for HU, prescription rates are low. Utilizing a scoping review approach, we summarized and synthesized relevant findings regarding provider barriers and facilitators to the prescription of HU in youth and adults with SCD and provided suggestions for future implementation strategies to improve prescription rates...
September 10, 2023: British Journal of Haematology
https://read.qxmd.com/read/37691005/polyclonal-immunoglobulin-recovery-in-patients-with-newly-diagnosed-myeloma-receiving-maintenance-therapy-after-autologous-haematopoietic-stem-cell-transplantation-with-either-carfilzomib-lenalidomide-and-dexamethasone-or-lenalidomide-alone-subanalysis-of-the
#19
JOURNAL ARTICLE
Tadeusz Kubicki, Dominik Dytfeld, Tomasz Wróbel, Krzysztof Jamroziak, Paweł Robak, Jarosław Czyż, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Tomasz Szczepaniak, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Łukasz Szukalski, Jan Maciej Zaucha, Damian Mikulski, Olga Czabak, Oscar B Lahoud, Andrew Stefka, Benjamin A Derman, Andrzej J Jakubowiak
Previous studies suggest that postautologous stem cell transplant (ASCT) recovery of polyclonal immunoglobulin from immunoparesis in patients with multiple myeloma is a positive prognostic marker. We performed a longitudinal analysis of polyclonal immunoglobulin concentrations and unique B-cell sequences in patients enrolled in the phase 3 ATLAS trial that randomized 180 subjects to either carfilzomib, lenalidomide, dexamethasone (KRd) or lenalidomide (R) maintenance. In the KRd arm, standard-risk patients with minimal residual disease negativity after six cycles de-escalated to R alone after cycle 8...
September 10, 2023: British Journal of Haematology
https://read.qxmd.com/read/37690811/outcome-after-chimeric-antigen-receptor-car-t-cell-therapy-failure-in-large-b-cell-lymphomas
#20
JOURNAL ARTICLE
Anna Dodero, Stefania Bramanti, Martina Di Trani, Martina Pennisi, Silva Ljevar, Annalisa Chiappella, Magagnoli Massimo, Anna Guidetti, Francesco Corrado, Paulina Maria Nierychlewska, Alice Di Rocco, Daniele Lorenzini, Rahal Daoud, Chiara De Philippis, Armando Santoro, Carmelo Carlo-Stella, Paolo Corradini
This study retrospectively evaluated the outcome of salvage therapy in 51 patients who failed axicabtagene ciloleucel or tisagenlecleucel for relapsed/refractory large B-cell lymphomas. Of these patients, 22 (43%) were enrolled in clinical trials (glofitamab or loncastuximab tesirine + ibrutinib), whereas 29 received standard therapies (lenalidomide [Len], checkpoint inhibitors [CPIs], ibrutinib [I], chemoimmunotherapy and radiotherapy) or supportive care. Overall, 26 of 39 (67%) treated patients received a treatment based on immunotherapy (glofitamab, CPI, Len) that was mainly represented by bispecific antibody (n = 18)...
September 10, 2023: British Journal of Haematology
journal
journal
20057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.